Read our latest updates & insights

On 8 May 2024, Telix announced an agreement with Cardinal Health Nuclear & Precision Health Solutions for the global clinical supply of actinium-225 (Ac-225). This therapeutic radioisotope will support the development of Telix’s targeted alpha therapy (TAT) pipeli...

On 7 May 2024, Galderma announced that its nemolizumab, for the treatment of prurigo nodularis and for moderate to severe atopic dermatitis has been accepted for review in Australia, Singapore, Switzerland and the UK under the Access Consortium Framework, a collaboration be...

On 7 May 2024, the EU Medicines Agency (EMA) withdrew marketing authorisation (MA) approval for AZ’s COVID-19 vaccine Vaxzevria, at AZ’s request. AZ requested   the withdrawal reportedly due to decline in demand for the vaccine and it no longer being manufactured or s...

On 7 May 2024, Pharma In Focus reported that Arrotex has partnered with Amgen to promote Amgen’s Prolia® (denosumab) in Australia.  It is planned that the partnership “will support the future growth of Prolia in the Australian market, utilising the infrastructure and reach ...

On 7 May 2024, Sandoz announced Q1 2024 net sales of USD1.9 billion, with its biosimilars growing 21% to USD 623 million.  The biosimilar growth is said to be driven by Sandoz’s 2023 US/EU launch of Hyrimoz®, biosimilar to AbbVie’s Humira® (adalimumab), and the acquisition ...

On 6 May 2024, Calliditas announced positive Phase 2 results for Setanaxib and Pembrolizumab for the treatment of head and neck cancer.  The trial was randomized, placebo-controlled, and double-blinded and patients completed at least 15 weeks of treatment with 800mg setanax...

On 3 May 2024, Indian-headquartered Lupin, in partnership with Sandoz, announced its Canadian launch of etanercept biosimilar Rymti®, biosimilar to Amgen’s Enbrel®, with a full indication set.  Rymti® is supplied in a pre-filled pen and syringe and is Lupin’s fi...